Navigation Links
Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Date:5/23/2013

SAN DIEGO, May 23, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of David A. Ramsay as Chief Financial Officer.  Mr. Ramsay was most recently Vice President, Corporate Development at Halozyme.

 (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)    

"With his established financial management experience and his recent commercial and operational experience gained by working in our commercial group for the last four years, David brings strong assets to advance the company, manage financial growth and deliver value for our shareholders," said Gregory I. Frost , Ph.D., President and Chief Executive Officer at Halozyme.  Mr. Ramsay replaces Kurt Gustafson who is leaving the company to pursue other opportunities. "We wish Kurt the best and sincerely thank him for his years of service helping to build our business," continued Frost. 

Mr. Ramsay has had a distinguished tenure at Halozyme, joining in 2003 as Chief Financial Officer before serving as Vice President, Corporate Development. His numerous achievements and accomplishments at Halozyme include spearheading the process of taking Halozyme public in 2004, negotiating and executing equity investments made by Roche and Baxter, negotiating and signing the Baxter Hylenex collaboration, and ultimately leading the effort to reintroduce Hylenex to the market in late 2011.  Prior to Halozyme, he served in various financial roles including Vice President, Chief Financial Officer of Lathian Systems.  Prior to Lathian, Mr. Ramsay was Vice President, Treasurer of ICN Pharmaceuticals, now called Valeant Pharmaceuticals International, a multinational, specialty pharmaceutical company.  Mr. Ramsay joined Valeant from ARCO, where he spent four years in various financial roles, most recently serving as Manager, Financial Planning & Analysis for the company's Retail Marketing division.

About Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need.  The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma, Intrexon, and Pfizer. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Reports First Quarter 2013 Financial Results
2. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
3. Halozyme Therapeutics Names Matt Posard to Board of Directors
4. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
5. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
6. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
7. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Halozyme to Host Third Quarter Financial Results Conference Call
10. Halozyme Reports Second Quarter 2012 Financial Results
11. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):